Effects of UroVaxom on Urinary Tract Infection After Ureteroscopic Lithotripsy: A Multicenter Prospective Randomized Study
4 affiliations
- 1Department of Urology, Kyungpook National University Hospital, Daegu 41944, Republic of Korea
- 2Department of Urology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju 61469, Republic of Korea
- 3Department of Urology, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan 48108, Republic of Korea
- 4Department of Urology, School of Medicine, Kyungpook National University, Daegu 41566, Republic of Korea
Abstract
Background/Objectives: To evaluate whether perioperative UroVaxom reduces postoperative urinary tract infection-related findings after ureteroscopic lithotripsy. Methods: In this prospective, randomized, multicenter study, patients with a history of recurrent UTI who were scheduled to undergo ureteroscopic lithotripsy for unilateral renal or ureteral stones < 2 cm were assigned to UroVaxom 60 mg or placebo once daily for 1 week before and 2 weeks after surgery. Baseline characteristics, surgical outcomes, postoperative UTI, pyuria, bacteriuria, serum C-reactive protein (CRP), and adverse events were compared. Results: Of 73 screened patients, 57 were analyzed (placebo, n = 29; UroVaxom, n = 28). Baseline characteristics were comparable between groups. Operative time, hospital stay, and stone-free rate did not differ significantly. Febrile UTI occurred in 1 patient (3.4%) in the placebo group and in none of the UroVaxom group. At 1 month, pyuria and bacteriuria were significantly less frequent in the UroVaxom group, and mean serum CRP was also significantly lower. Adverse events were uncommon and similar between groups. Conclusions: Although this study did not demonstrate that perioperative UroVaxom significantly reduced the incidence of postoperative febrile urinary tract infection compared with placebo after ureteroscopic lithotripsy, UroVaxom was associated with lower rates of postoperative pyuria and bacteriuria and lower serum CRP levels at 1 month without increasing adverse events.
Related
- Case Report: Renal rupture and massive urine extravasation following flexible ureteroscopic lithotripsy: analysis of 4 cases and literature review
- Current evidence of flexible ureteroscopic laser lithotripsy under local anesthesia: feasibility, safety, and clinical application.
- Ureteral stricture prediction of occurrence after ureteroscopic lithotripsy.
- Intelligent versus flexible negative-pressure aspiration sheath for ureteroscopic lithotripsy: a single-center retrospective study with systematic review and meta-analysis.
- Day 3 blood urea nitrogen and discharge disposition in patients with pleural infection: a multicenter prospective study
BibTeX
@article{lee2026effects,
title = {{Effects of UroVaxom on Urinary Tract Infection After Ureteroscopic Lithotripsy: A Multicenter Prospective Randomized Study}},
author = {Sang Hee Lee and Kyung-Jin Oh and Ho Seok Chung and Cheol Kyu Oh and Myungchan Park and Hyun Tae Kim and Bum Soo Kim},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15207938},
url = {https://www.mdpi.com/2077-0383/15/20/7938},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Effects of UroVaxom on Urinary Tract Infection After Ureteroscopic Lithotripsy: A Multicenter Prospective Randomized Study
AU - Sang Hee Lee
AU - Kyung-Jin Oh
AU - Ho Seok Chung
AU - Cheol Kyu Oh
AU - Myungchan Park
AU - Hyun Tae Kim
AU - Bum Soo Kim
PY - 2026
DA - 2026/10/01
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15207938
UR - https://www.mdpi.com/2077-0383/15/20/7938
AB - Background/Objectives: To evaluate whether perioperative UroVaxom reduces postoperative urinary tract infection-related findings after ureteroscopic lithotripsy. Methods: In this prospective, randomized, multicenter study, patients with a history of recurrent UTI who were scheduled to undergo ureteroscopic lithotripsy for unilateral renal or ureteral stones < 2 cm were assigned to UroVaxom 60 mg or placebo once daily for 1 week before and 2 weeks after surgery. Baseline characteristics, surgical outcomes, postoperative UTI, pyuria, bacteriuria, serum C-reactive protein (CRP), and adverse events were compared. Results: Of 73 screened patients, 57 were analyzed (placebo, n = 29; UroVaxom, n = 28). Baseline characteristics were comparable between groups. Operative time, hospital stay, and stone-free rate did not differ significantly. Febrile UTI occurred in 1 patient (3.4%) in the placebo group and in none of the UroVaxom group. At 1 month, pyuria and bacteriuria were significantly less frequent in the UroVaxom group, and mean serum CRP was also significantly lower. Adverse events were uncommon and similar between groups. Conclusions: Although this study did not demonstrate that perioperative UroVaxom significantly reduced the incidence of postoperative febrile urinary tract infection compared with placebo after ureteroscopic lithotripsy, UroVaxom was associated with lower rates of postoperative pyuria and bacteriuria and lower serum CRP levels at 1 month without increasing adverse events.
SN - 2077-0383
ER -